AMGEN Inc

NASDAQ: AMGN
$297.78
-$10.03 (-3.3%)
Closing Price on February 6, 2025

AMGN Articles

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in how the reports look, and it could throw a wild card report...
ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is that after years of...
Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many of...
Amgen submitted an SEC Filing showing that, as of April 1, one of its subsidiaries and a GlaxoSmithKline subsidiary have terminated part and amended part of a collaboration agreement from 2009.
Jon OggMost investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs...
In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples in years are very attractive for many investors. Here are the top names rated Outperform...
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage of...
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, March 27, 2014. They include Apple, BlackBerry, Chesapeake Energy, Citigroup and King...
After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early March, especially in Celgene, Medivation and Pharmacyclics.
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a perfect entry point for...
In a new report out from Jefferies, the analysts posted a complete list of the cheapest, on a P/E basis, of the top health care stocks to buy now. Investors concerned about the toppy market may want...
In a new research report from Deutsche Bank, the equity strategists point that the companies that are maintaining and increasing share buybacks, plus maintaining and increasing dividends, are the...
The pricier the stock market gets, the more important it is for investors to keep a close eye on what they are paying for stocks. Flashy momentum stocks are great for traders, but investors need...
Biotech and emerging pharmaceutical stocks continue to be hot, but short sellers shied away from many of them in late February. Those bucking that trend include BioMarin Pharmaceutical and Medivation.
After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical stocks in early February. The largest upswings happened to BioMarin...
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.